Lexeo Therapeutics, Inc.: STATE STREET CORP discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
State Street Corp. disclosed a stake exceeding 5% in Lexeo Therapeutics Inc. via a Schedule 13G filing with the SEC (accession 0000093751-26-000685). The filing signals that the institutional investor has crossed the key 5% beneficial ownership threshold in the gene therapy developer. Such 13G disclosures are typically passive in nature, indicating the position was not taken with intent to influence control of the company. The exact share count and percentage were not specified in the filing summary. Investors will watch for further 13G amendments or 13D filings to gauge whether State Street's position remains passive or becomes activist.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
State Street Corp, Lexeo Therapeutics, Inc.